| Authors: |
Kamudoni P; Global Evidence & Value Development - R&D, Merck Healthcare KGaA, Darmstadt, Germany., Amtmann D; Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA., Johns J; Institute of Medicines Development, Cardiff, UK., Cook KF; Feral Scholars,Broaddus, TX, USA., Salem R; Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA., Salek S; School of Life & Medical Sciences, University of Hertfordshire, Hatfield, UK., Raab J; Global Evidence & Value Development - R&D, Merck Healthcare KGaA, Darmstadt, Germany., Middleton R; UK MS Register, Swansea University Medical School, Swansea, UK., Repovic P; Swedish Medical Center, Seattle, WA, USA., Alschuler KN; Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA.; Department of Neurology, University of Washington, Seattle, WA, USA., Geldern GV; Department of Neurology, University of Washington, Seattle, WA, USA., Wundes A; Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA.; Department of Neurology, University of Washington, Seattle, WA, USA., Barrett A; Patient-Centered Outcomes Assessment, RTI Health Solutions, Research Triangle Park, NC, USA., Olayinka-Amao O; Patient-Centered Outcomes Assessment, RTI Health Solutions, Research Triangle Park, NC, USA., Henke C; Global Evidence & Value Development - R&D, Merck Healthcare KGaA, Darmstadt, Germany. |
